HomeThemesTypesDBAbout
Showing: ◈ news×◈ MHRA×
David Meek, the CEO of Ipsen, warns Britain leaving the European Union has seen the country fall down the list of priorities.
And it will cost more here because of the UK pulling out of the European Medicines Agency on 30 December.
Britain’s medicines regulator has contradicted claims by health secretary Matt Hancock that the UK got the first coronavirus vaccine faster because of Brexit.
Education secretary lauds vaccine rollout saying scientists in UK better than in France, Belgium or US.
This being 2020, it didn't take long for good news about the Pfizer/BioNTech jab to turn into a tiresome row about Brexit.
Kate Bingham contradicts Matt Hancock's claim UK authorities backed jabs swiftly "because of Brexit".
Verdict has conducted a poll to analyse whether medical devices in the UK will continue to have a high degree of safety until all new post-Brexit regulations come into effect by 2023.
The new European Union (EU) Medical Devices Regulation (MDR) and In Vitro Diagnostic Medical Devices Regulation (IVDR) are due to be implemented across the EU from May 2021.
The UK’s MHRA may have to lay off about 300 of its 1,200 employees, thanks to a decline in income due to reduced medical product submissions following Brexit, spurring anger among unions across the island.
Trade unions and regulatory experts warn that budget and staff cuts may lead to drug approval delays or the UK regulator simply rubber-stamping EMA decisions.
Informa Pharma Intelligence (IPI) has found that some drug firms may withdraw up to 90% of their products from Northern Ireland, once the Brexit grace period has passed.
A new video by Peter Stefanovic rubbished Johnson's claim that the vaccine rollout's success was down to Brexit.
UK drug distributors and those involved in the parallel importing of drugs have told the parliamentary Health Select Committee that they want to see the UK remain in the customs union and the single market.
Britain must work with other countries to prevent friction on medicine rules post-Brexit to avoid being sidelined by the global drug industry, according to a report from the U.K.’s biggest pharmaceutical lobby group.
The UK’s medicines and devices regulator will stop work that “does not add value” and lose over 100 full time equivalent staff posts as part of its post-Brexit cost cutting drive, a leaked consultation document seen by The BMJ shows. / But experts warned that plans to streamline regulation to speed up the development and approval of new drugs for patients’ benefit carried potential safety risks.
There are a number of measures that the UK Government must take in order to address the challenges of leaving the EU's single market.
BREXIT is causing “damage across the board” to UK science, including missing out on more than £1 billion in funding, campaigners have warned.
Fears extra expense and paperwork caused by Brexit will make Britain unattractive to global drugmakers.
Six years after the referendum we can disentangle the evidence and judge the effects on health and care, says Richard Vize.
As of December 2022, UK companies importing medicines from the EU may need to set up new batch testing facilities. What will this mean for the industry and how did the situation come about?
With the exception of the very lowest risk devices, manufacturers must apply to a UK approved body. Only after they have UKCA certification can their products be placed on the market in England, Wales and Scotland.
There are growing post-Brexit differences between which medicines are approved for use in Northern Ireland and the rest of the UK, research from a health think tank indicates.
Specialisms such as dentistry have shortages and EU exit still causes issues with medicines in Northern Ireland, thinktank finds.
A House of Lords committee will discuss the impact of the Northern Ireland protocol on medicine supplies in Northern Ireland.
On the third anniversary of Brexit, Boris Johnson has attempted to paint the withdrawal from the EU as a major boost for the UK – but immediately faced pushback over a questionable claim.